Germany FacilitySpanish pharmaceutical firm and maker of skin medicines employs PAS-X system for its entire manufacturing process Spanish pharmaceutical firm and maker of skin medicines employs PAS-X system for its entire manufacturing process including packaging.“Feel the science” is a tagline used by Almirall Spain-based manufacturer of dermatologicals/skin medicines The pharmaceutical company’s products are available in more than 70 countries Almirall recently opted for Werum’s PAS-X Manufacturing Execution System to be installed in its plant in Reinbek PAS-X will be rolled out as a full-scope Manufacturing Execution System (MES) for the entire manufacturing process—including weighing It will replace the facility’s legacy production management system The new review and release workflows aim to more effective processes as well as compliance with regulatory requirements PAS-X will be implemented out of the box per Werum’s implementation method of “Ready,” “Fit,” “Build” and “Run.” The benefits for Almirall include short project term and significant cost efficiency “We are already thrilled about the Fit Phase,” says Maik Weber “Together with the Werum consultants we matched our business processes in the Reinbek production site with the best practice-based PAS-X workflows Both the approach and the expertise of the consultants and the results of this phase were really convincing.” Werum IT Solutions supplies MES and manufacturing IT products for the pharmaceutical and biopharmaceutical industries. Werum is part of Medipak Systems, the Pharma Systems business area of the international technology group Körber. Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing COVID-19 booster shots to shore up Americans’ protection against the virus. How much the manufacturers stand to gain depends on how big the rollout proves to be. The Biden administration last month announced plans to give boosters to nearly everybody. But U.S. regulators have rejected the across-the-board approach and instead said third shots of Pfizer’s vaccine should go to people who are 65 and older and certain others at high risk from COVID-19. Still, the crisis is constantly evolving, and some top U.S. health officials expect boosters will be more broadly authorized in the coming weeks or months. And that, plus continued growth in initial vaccinations, could mean a huge gain in sales and profits for Pfizer and Moderna in particular. “The opportunity quite frankly is reflective of the billions of people around the world who would need a vaccination and a boost,” Jefferies analyst Michael Yee said. Wall Street is taking notice. The average forecast among analysts for Moderna’s 2022 revenue has jumped 35% since President Joe Biden laid out his booster plan in mid-August. Most of the vaccinations so far in the U.S. have come from Pfizer, which developed its shot with Germany’s BioNTech, and Moderna. They have inoculated about 99 million and 68 million people, respectively. Johnson & Johnson is third with about 14 million people. No one knows yet how many people will get the extra shots. But Morningstar analyst Karen Andersen expects boosters alone to bring in about $26 billion in global sales next year for Pfizer and BioNTech and around $14 billion for Moderna if they are endorsed for nearly all Americans. Those companies also may gain business from people who got other vaccines initially. In Britain, which plans to offer boosters to everyone over 50 and other vulnerable people, an expert panel has recommended that Pfizer’s shot be the primary choice, with Moderna as the alternative. Andersen expects Moderna, which has no other products on the market, to generate a roughly $13 billion profit next year from all COVID-19 vaccine sales if boosters are broadly authorized. Potential vaccine profits are harder to estimate for Pfizer, but company executives have said they expect their pre-tax adjusted profit margin from the vaccine to be in the “high 20s” as a percentage of revenue. That would translate to a profit of around $7 billion next year just from boosters, based on Andersen’s sales prediction. J&J and Europe’s AstraZeneca have said they don’t intend to profit from their COVID-19 vaccines during the pandemic. For Pfizer and Moderna, the boosters could be more profitable than the original doses because they won’t come with the research and development costs the companies incurred to get the vaccines on the market in the first place. WBB Securities CEO Steve Brozak said the booster shots will represent “almost pure profit” compared with the initial doses. Drugmakers aren’t the only businesses that could see a windfall from delivering boosters. Drugstore chains CVS Health and Walgreens could bring in more than $800 million each in revenue, according to Jeff Jonas, a portfolio manager with Gabelli Funds. Jonas noted that the drugstores may not face competition from mass vaccination clinics this time around, and the chains are diligent about collecting customer contact information. That makes it easy to invite people back for boosters. Drugmakers are also developing COVID-19 shots that target certain variants of the virus, and say people might need annual shots like the ones they receive for the flu. All of that could make the vaccines a major recurring source of revenue. The COVID-19 vaccines have already done much better than their predecessors. Pfizer said in July it expects revenue from its COVID-19 vaccine to reach $33.5 billion this year, an estimate that could change depending on the impact of boosters or the possible expansion of shots to elementary school children. That would be more than five times the $5.8 billion racked up last year by the world’s most lucrative vaccine — Pfizer’s Prevnar13, which protects against pneumococcal disease. It also would dwarf the $19.8 billion brought in last year by AbbVie’s rheumatoid arthritis treatment Humira, widely regarded as the world’s top-selling drug. This bodes well for future vaccine development, noted Erik Gordon, a business professor at the University of Michigan. Vaccines normally are nowhere near as profitable as treatments, Gordon said. But the success of the COVID-19 shots could draw more drugmakers and venture capitalists into the field. “The vaccine business is more attractive, which, for those of us who are going to need vaccines, is good,” Gordon said. Thank you. Please check your inbox to confirm. © 1996 - 2025 NewsHour Productions LLC. All Rights Reserved. PBS is a 501(c)(3) not-for-profit organization. Subscribe to Here's the Deal with Lisa Desjardins Holmium Laser Enucleation of the Prostate (HoLEP) is established as an effective transurethral treatment option for LUTS due to BPH with improved postoperative outcome. The aim of this study was to evaluate the medium-term results by patient reported outcome measurement and to detect potential risk factors for postoperative complications or impaired outcome. We performed a retrospective single-center cohort study including all patients undergoing HoLEP in the study center between April 2019 and December 2021. Therefore, perioperative parameters and postoperative outcome was documented and all patients were asked for their outcome (PROM), complications, IPSS, QoL and changes in sexual and continence function by a questionnaire at a single time point. The overall satisfaction with the procedure and its results are high. We could not identify any independent risk factors for postoperative complications after HoLEP. The used questionnaire is a simple tool for postoperative patient reported outcome measurement with a good correlation to clinical parameters. Volume 11 - 2024 | https://doi.org/10.3389/fsurg.2024.1358701 Introduction: Holmium Laser Enucleation of the Prostate (HoLEP) is established as an effective transurethral treatment option for LUTS due to BPH with improved postoperative outcome The aim of this study was to evaluate the medium-term results by patient reported outcome measurement and to detect potential risk factors for postoperative complications or impaired outcome Methods: We performed a retrospective single-center cohort study including all patients undergoing HoLEP in the study center between April 2019 and December 2021 perioperative parameters and postoperative outcome was documented and all patients were asked for their outcome (PROM) QoL and changes in sexual and continence function by a questionnaire at a single time point a total of 541 patients with a mean age of 72.5 ± 8.4 years were treated by HoLEP in the study center 71.7% of the questionnaires were returned after a mean observation period of 14.9 ± 6.3 month 91% of the patients reported to the single-timepoint questionnaire reporting a good satisfaction with the procedure and a low postoperative complication rate The international prostate symptom score could be reduced significantly to 6.2 ± 5.7 (preoperative 19.0 ± 7.2; p < 0.001) Patients with an ASA score ≥ 3 prostate volume > 80 ml medication with platelet inhibitors or DOAK or preoperative need of an indwelling catheter didn't show an increased complication rate Conclusion: The overall satisfaction with the procedure and its results are high We could not identify any independent risk factors for postoperative complications after HoLEP The used questionnaire is a simple tool for postoperative patient reported outcome measurement with a good correlation to clinical parameters The transurethral resection of the prostate (TUR- P) has been considered to be the reference procedure in the interventional therapy. Beside this procedure different laser-assisted techniques have been established which use different techniques of tissue ablation—vaporization, resection or enucleation (7) The optimal tool for this evaluation and the impact of postoperative complications and risk factors on patients' satisfaction are still under discussion The aim of this study was to evaluate risk factors for postoperative complications and impaired outcome after HoLEP and to determine the accuracy of the PROM using the PGI-I in an unselected “real-life” patient cohort in a single center retrospective cohort study All patients who underwent HoLEP for the treatment of BPS between April 2019 and December 2021 were included into this retrospective cohort study. There were no exclusion criteria. The indication for enucleation was made in accordance with the national guidelines (13) the change in sexual function and urinary continence For the last two questions used the same graduation like the PGI-I Patient global impression of Improvement (PGI-I) questionnaire patients' preoperative characteristics were extracted from the medical records as well as ASA status and preoperative medical conditions and medication Preoperative prostate volume and postoperative histology were additionally extracted We considered the weight of the resected tissue the postoperative hospital length of stay and the blood transfusion rate as peri- and postoperative parameters Transient incontinence after HoLEP is an issue. In more than 80% of the patient's recovery takes less than 3 months (28) It was aimed to evaluate the results after the complete recovery of the patients the questionnaire was sent to the patients no earlier than 6 months after surgery to assess the results after complete recovery An additional postoperative visit of the patient for postoperative assessment was not performed The preoperative work-up included a urine test and preoperative antibiotic therapy was given for at least 3 days and continued postoperatively A transurethral catheter was changed preoperatively Patients with normal urine findings received only perioperative antibiotic prophylaxis with a second-generation cephalosporin A monotherapy with antiplatelet agent was continued throughout the surgical procedure Anticoagulation agents were stopped 48 h before surgery and a bridging therapy was started depending on indication and patients' characteristics An incision was performed at the 5 o'clock position to reach the surgical capsule As soon as the apical adenoma was dissected from the capsule the mucosa at the sphincter region was incised to avoid unnecessary tension to the sphincter region The lateral lobes were separated ventrally with a 12 o'clock incision After enucleation of the left lateral lobe the medium and right lateral lobe were removed together The adenoma was removed from the urinary bladder using a morcellator (Piranha; Richard Wolf GmbH A transurethral 3-way-irrigation catheter with a diameter of 22 charrier was inserted and blocked in the prostate fossa A continuous irrigation with saline was started and continued throughout the postoperative period The transurethral catheter was removed within 48 h after surgery in the absence of bleeding residual urinary sonography was performed and the patients were discharged if findings were inconspicuous In case of larger amounts of residual urine an individual decision was made on the insertion of a new transurethral catheter anticoagulation therapy was started again 48 h after surgery Ethical approval was waived by the Ethics Committee of the Medical Association Schleswig-Holstein due to data protection of the data collected by the retrospective non-interventional study design Additional written informed consent was not needed The study has been submitted and registered in the German Register of Clinical Trials (DRKS00024746) Statistical analysis was performed using SPSS version 29 (IBM Univariate analyses were performed using t-test and Mann–Whitney-U-test for continuous variables Chi-Square test or Fisher's exact test was used for categorial data Results are given in mean with standard deviation for continuous variables and as percentage for categorical variables Comparing two groups before and after surgery All reported p-values were considered statistically significant if p < 0.05 The data presented in this study are reported in concordance with the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) criteria (30) an unselected cohort of 541 patients were treated with HoLEP for symptomatic benign prostate enlargement changes in sexual and continence function and patient global impression of improvement was sent to all patients with a response rate of 71.7% (388 patients) This questionnaire was sent at least 6 months after surgery with a mean follow-up-period of 14.9 ± 6.3 months  Table 2 shows the baseline characteristics of the study cohort Baseline characteristics of the study cohort (N = 388) The HoLEP procedure toke 63.0 ± 27.9 min and resected an adenoma with a median of 52.7 ± 35.3 g The median length of postoperative stay was 2.51 ± 3.3 days with a transfusion rate of 0% a major complication rate of 1.8% within the follow-up period was reported in the cohort tamponade of the urinary bladder or need for bladder neck incision 12.6% reported ambulant treated postoperative complications such as urinary tract infection whereas 6.7% needed an additional treatment in the hospital by continuous irrigation due to bleeding or intravenous antibiotics We evaluated potential risk factors for postoperative complications but could not identify any significant correlation between anticoagulation treatment (12.4% without and 15.9% with complication; p = 0.461) large prostate volume >80 ml (39.0% without and 43.2% with complication; p = 0.491) urinary retention with presence of an indwelling catheter at time of surgery (34.0% without and 34.1% with complication; p = 0.978) or ASA status ≥3 (33.0% without and 35.4% with complication; p = 0.688) None of these factors caused a higher rate of readmission or intervention under local or general anesthesia There was a significant change in the IPSS comparing before and after HoLEP (19.0 ± 7.2 vs. 6.2 ± 5.7; p < 0.001). Table 3 provides an overview of the postoperative functional outcomes changes in sexual function and the improvement of continence influenced the PGI-I significantly Comparison of the patients answering the questionnaire regarding postoperative satisfaction The used PGI-I showed a good correlation between reported satisfaction and the postoperative IPSS (Figure 1) Correlation between patient global impression of improvement (PGI-I) and postoperative IPSS This rate was significant lower in the group of satisfied patients (p < 0.001) C) and (D): 1: much better; 2: better; 3: a little better; 4: no change; 5: a little worse; 6: worse; 7: much worse This study underlines the effectiveness and safety of HoLEP using a high power Holmium Laser even in high-risk patients with anticoagulation and high prostate volume The patients' satisfaction rate in this study cohort is high and easily measurable by a simple questionnaire (PGI-I) showing a good correlation to the postoperative IPSS and postoperative complications This stresses the importance of PROM in the indication and quality control for surgical procedures The design of the questionnaire and the reported high correlation with the IPSS helps to establish an interview-based follow-up ensuring the measurement of patients' postoperative outcome BPS and associated LUTS are benign diseases of aging men and are not deemed life-threatening, but they can have an apparently negative impact on patient´s QoL (6) measuring postoperative QoL is an important tool to evaluate the patients' satisfaction and outcome The used PGI-I correlated well with the postoperative IPSS the occurrence of complications and the impact on the sexual function this simple and short questionnaire seems to be a valuable tool for a postoperative assessment after HoLEP Due to demographic change, the proportion of older patients will increase. It has been shown in several studies, that elderly patients benefit from a gentle procedure such as HoLEP (33, 34) Especially patients with a large prostate and a high weight of the resected tissue were satisfied with the procedure and their results This might be due to the preoperative burden In larger glands obstruction as the most prevalent reason for LUTS is more likely While the preoperative IPSS did not differ significantly between both groups, the postoperative IPSS could be correlated with the postoperative satisfaction (Figure 1). The postoperative IPSS measured in this study is comparable to previously reported IPSS after HoLEP (1, 38) The comparability to other studies evaluating the postoperative IPSS after HoLEP is limited due to the evaluation at a single time-point without a longitudinal measurement Postoperative satisfaction rate after surgical interventions for BPS has been evaluated in several studies (1, 39–41) showing good results and are comparable to the 91% satisfaction rate reported in this study cohort The major limitation of this study is its retrospective single-center design only limited longitudinal data are available and no preoperative quality of life is documented there is no internal or external control group reporting for example the outcome and quality of life after TUR-P in comparison to HoLEP so an inter-group or pairwise comparison was not achievable The survey period covers a very long period of time (6–27 month after surgery) which makes it difficult to evaluate especially the short- and long- time outcome The age of the study cohort might influence some of the presented outcome parameters and make a long-term follow-up difficult Since we did not define any exclusion criteria preoperatively parameters such as Qmax and IPSS could not be collected in patients with preoperative catheter All data regarding patient reported quality of life are limited by the subjective evaluation of every single patients so a longitudinal evaluation comparing pre- and postoperative quality of life in the same patient would be a good basis for further research such as the recently published telemonitoring might help to evaluate postoperative outcome this technique is limited by the costs and patient's age restricting the use of new technologies low-complication surgical procedures for symptomatic BPS for an unselected patient population is very important due to demographical changes The HoLEP in two lobe technique was also confirmed in our study as a cohort-independent safe procedure that leads to high patient satisfaction and a significant improvement in urination ASA score or preoperative anticoagulation did not show a significant influence on perioperative morbidity It is important in the indication of a surgical procedure for benign lesions to include the patient reported outcome in the assessment and the follow-up The data presented here show a good correlation between IPSS and PGI-I for postoperative patients' satisfaction Further studies are needed to evaluate this in a longitudinal setting such as TUR-P or conservative treatments will help to define the best treatment for each patient this study showed a high procedure-specific satisfaction rate with a low complication rate even for older patients with multiple comorbidities and the need of anticoagulation the routine evaluation of patient-reported outcome can help choose the right treatment for each patient The raw data supporting the conclusions of this article will be made available by the authors The studies involving humans were approved by Ethics Committee of the Medical Association Schleswig-Holstein The studies were conducted in accordance with the local legislation and institutional requirements The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants’ legal guardians/next of kin because of the retrospective non-interventional study design The author(s) declare that no financial support was received for the research The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher Patient satisfaction after holmium laser enucleation of the prostate (HoLEP): a prospective cohort study PubMed Abstract | Crossref Full Text | Google Scholar Tamsulosin plus a new complementary and alternative medicine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a retrospective comparative study Arch Ital di Urol Androl Organo Uff [di] Soc Ital di Ecogr Urol e Nefrol European prospective investigation into cancer and nutrition (EPIC): study populations and data collection 5. Ng M, Baradhi KM. Benign Prostatic Hyperplasia. Treasure Island (FL): StatPearls Publishing (2023). Available online at: http://www.ncbi.nlm.nih.gov/pubmed/16985902 (accessed November 22 The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement Transurethral procedures in the treatment of benign prostatic hyperplasia: a systematic review and meta-analysis of effectiveness and complications Holmium laser enucleation of the prostate: patient selection and outcomes PubMed Abstract | Crossref Full Text | Google Scholar Experience with more than 1,000 holmium laser prostate enucleations for benign prostatic hyperplasia 18 years of holmium laser enucleation of the prostate: a single center experience Is holmium laser enucleation of the prostate a good surgical alternative in benign prostatic hyperplasia management Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience 13. Deutsche Gesellschaft für Urologie e.V. S2e-Leitlinie Diagnostik und Therapie des Bedingen Prostatasyndroms. (2023). Available online at: Available at: https://register.awmf.org/assets/guidelines/043-034l_S2e_Diagnostik_Therapie_benignes_Prostatasyndrom_2023-04.pdf (accessed November 22 Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023 holmium laser enucleation of the prostate (HoLEP) may be the new “gold standard” Shifting trends in prostate treatment: a systematic review comparing transurethral resection of the prostate and holmium laser enucleation of the prostate Holmium laser enucleation of the prostate: a review of the clinical trial evidence PubMed Abstract | Crossref Full Text | Google Scholar Holmium laser enucleation of the prostate: efficacy safety and preoperative management in patients presenting with anticoagulation therapy Perioperative safety in patient under oral anticoagulation during holmium laser enucleation of the prostate Holmium laser enucleation of the prostate: comparison of immediate postoperative outcomes in patients with and without antithrombotic therapy A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years A novel low-cost uroflowmetry for patient telemonitoring Validation of a patient reported outcome questionnaire for assessing success of endoscopic prostatectomy Differences in patient-reported outcomes that are most frequently detected in randomized controlled trials in patients with solid tumors: a pooled analysis of 229 trials Quality of life in patients with rectal resections and End-to-End primary anastomosis using a standardized perioperative pathway Current status and role of patient-reported outcome measures (PROMs) in endourology Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Holmium laser enucleation of the prostate is associated with complications and sequelae even in the hands of an experienced surgeon following completion of the learning curve Comparison of 3 different enucleation techniques of holmium laser enucleation of prostate (HoLEP) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies Quality of life and outcome after holmium laser enucleation of the prostate (HoLEP) Age-stratified outcomes of holmium laser enucleation of the prostate Holmium laser enucleation of the prostate is safe for patients above 80 years: a prospective study Holmium laser enucleation of the prostate in patients requiring anticoagulation Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) on patients receiving dual antiplatelet therapy (DAPT) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction Holmium laser enucleation of the prostate: long-term durability of clinical outcomes and complication rates during 10 years of followup Holmium laser enucleation of the prostate: results at 6 years Clinical evaluation of transurethral versus transvesical prostatectomy Evaluation of immediate and late results of transurethral resection of the prostate and functional results amongst different modifications of endoscopic enucleation of the prostate (EEP): a systematic review and meta-analysis Comparison of postoperative stress urinary incontinence between anteroposterior dissection and modified gilling method in holmium laser enucleation of the prostate Holmium laser enucleation of the prostate with virtual basket mode: faster and better control on bleeding A randomized trial of holmium laser vs thulium laser vs bipolar enucleation of large prostate glands Assessing the outcome of holmium laser enucleation of the prostate by age and a history of blood thinning agents: report from a single-center series of >1800 consecutive cases The impact of complications and pain on patient satisfaction Brunken C and Herzberg J (2024) Patient reported outcome and quality of life measured by a simple questionnaire in patients with symptomatic benign prostate hyperplasia treated by holmium laser enucleation of the prostate (HoLEP) Received: 20 December 2023; Accepted: 15 January 2024;Published: 8 February 2024 © 2024 Schumacher, Marghawal, Brunken and Herzberg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) distribution or reproduction in other forums is permitted provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited in accordance with accepted academic practice distribution or reproduction is permitted which does not comply with these terms *Correspondence: Claus Brunken Y2xhdXMuYnJ1bmtlbkBrcmFua2VuaGF1cy1yZWluYmVrLmRl Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher 94% of researchers rate our articles as excellent or goodLearn more about the work of our research integrity team to safeguard the quality of each article we publish German tea exports grew significantly and imports were up 5.6% to meet demand from several of the world’s oldest and most respected tea blenders Gebrüder Wollenhaupt is one of the leading premium tea companies selling about 7,000 metric tons of tea and tea blends per year and flavors from 300 suppliers in 62 countries head of sales and division manager for tea at Wollenhaupt The company’s private label business offers 2,500 active recipes to suit nearly every customer “If a customer wants us to mix his own recipe we will make sure that he’ll be completely satisfied,” said Brinmühl a family-run business for more than 130 years is located in the periphery of the old port city of Hamburg Germany’s domestic tea market is discerning favoring high-quality loose teas and single-estate or single-origin teas The country also imports a large volume of herbs because Germany actively supports the use of herbs for medicinal purposes Wollenhaupt’s newest line of herbal teas is blended for well-being:  Cleansing (“I feel pure”) Energy (“I feel awake”) and Defense (“I feel strong”) ‘Enjoy with confidence’ is the company’s motto reflecting the firm’s commitment to medicinal quality ingredients and pure teas people in Northern Germany have welcomed their friends and family during the dark and cold winter days with a hot cup of black tea sweetened with rock sugar called Kandis and heavy cream The tea pot and water kettle were left on the wood or coal burning stove all day to make sure that a cup of tea was available at any time “We want people to fully enjoy tea like in the old days That is why we make sure that the whole supply chain is safe We only use natural ingredients and teas of all origins We are a leaf tea specialist in the premium market,” said Brinmühl “We even take customer care a step further:  If someone wants to open a tea store or a quaint tea room we can help with store design display and the right assortment,” said Brinmühl during the past 15 years many more tea stores and tea rooms have sprung up throughout Germany and in many countries in Europe Tea retailing in the coastal areas of the United States is picking up as well Wollenhaupt supplies a broad line of teas that includes instant These teas are popular mostly in Southern Europe and Russia The company is not a major supplier because quality herbs and teas are just too expensive for this price-focused segment the single cup coffee business is gaining momentum with 27% in 2015 and in Germany even with 31.4% Does Marco see the same niche for tea as well “We are working on cup portion tea options and have created a special department that deals with cutting the tea leaves to the exact right grade ,” he said “We definitely see a future in cup portion tea offerings.” According to a recent study by the NCA – the National Coffee Association of America – traditional coffee – not gourmet – is consumed by significantly more customers aged 60+ while espresso-based beverages are consumed by significantly more proportions of customers aged 18-39 then those in older groups Does Marco see the same trend in the tea business our various shapes of transparent leaf teabags are designed so that the customer can see the beauty of the tea leaves where supermarkets tend to offer more premium teas as their younger clienteles savor teas with new and sophisticated aromas,” he said The well-being line is blended to appeal to this segment “Premium hot tea is mostly consumed during the fall and winter months This is at least true for Europe and the US,” Brinmühl explained “That is why Wollenhaupt created another business years ago: The company has become Europe’s leading importer of natural vanilla pods Fifteen percent of global vanilla passes through our warehouse we have created a thriving and very interesting year-round business,” he added More Americans Drink Coffee Each Day Than Any Other Beverage | NCA USA Powering Spring Tea Production with Electrical Upgrades to Boost Rural Revitalization | China Daily The Instant Coffee Boom is Changing Farmers' Fortunes | Bloomberg Brewing Change: How Suki Tea is Tackling the Tea Industry’s Hidden Environmental Costs | Forbes Bialetti Acquired by Chinese-Backed NUO Capital: A New Chapter for the Iconic Moka Pot Maker | Coffee Geography More News Tips The STiR Coffee and Tea Newsletter is sent two times each month with news updates important information, and upcoming events Ltd - STiR is the international coffee and tea industry magazine and website reports on news around the world You are viewing your 1 free article this month Maria B Campbell Associates has been appointed the UK literary scouts for German publisher Rowohlt Verlag and has been part of the Georg von Holtzbrinck Group since 1982 “We are delighted to be working with Nicola Bartels and her excellent team at Rowohlt and look forward hugely to the partnership,” said Elizabeth Cochrane “It will be a privilege to introduce new UK writers to a distinguished publisher that I have always admired for its quality and breadth.” Cochrane was made the director of Maria B Campbell Associates UK last year heading up the London office of the New York scouting agency The new partnership will take effect from 1st July Rowohlt publisher Nicola Bartels said: “I am delighted that with Maria B Campbell Associates we have been able to gain an experienced and excellently networked scouting agency for Rowohlt fiction and non-fiction in the UK I admire Elizabeth’s energy and passion for books her professionalism and her knowhow in the book as well as the film industry We look forward very much to working with her and her team.” As Eptechnologies celebrates its 10th anniversary growth and a transformation in the marine industry.EPT is pioneering the serial production of large electric and hybrid systems there was minimal interest in this type of technology EPT was founded by Kasper Falkenberg and started its journey in a modest 35 m² workshop in the small village of Broager the company relocated to a basement in Hamburg before expanding to a 100 m² facility in 2017 EPT had outgrown its premises and moved to a larger space spanning 260 m² and co-owner Marco Ottiker joined where its German branch is located today with 900 m² prompting the decision to rent an additional location in Denmark EPT acquired another building in Sønderborg which as of today has already reached capacity Today the team has grown to around 50 and continues to expand steadily EPT operates independently without any external investors backing its endeavors The company’s success is solely attributed to its internal resources and innovation The company generates an annual turnover of approximately 20 million Euros maintaining a positive cash flow consistently over the past five years EPTechnologies proudly just opened its new 1500 m² facility in Denmark This complex will focus on developing and manufacturing the electric sail drives drop-in units for power boats and it has 3 assembly lines for EPTs battery production With an advanced test lab and collaborative spaces the facility will stimulate innovation and growth to drive progress and new ideas in the maritime industry The day was celebrated with a large gathering of employees attended by the city’s mayor who delivered an inspiring speech a public/private partnership focused on sustainable growth unveiled their action plan for cost-effective decarbonization emphasizing the significant role companies like EPT play in the initiative showcasing EPT’s commitment to the global stage EPTs’ electric and hybrid propulsion systems have powered numerous vessels demonstrating their reliability and performance in real-world applications The fleet is accumulating thousands of Nm each month providing EPT with a wealth of experience By leveraging the latest advancements in electric motors EPT has redefined the standards of performance Top News,Greece Greece has approved an international tender for hydrocarbon exploration in four blocks in the Mediterranean Sea Top News,World Top News,Energy World,Word newsletter The Panama Maritime Authority (PMA) participated in the 2025 edition of Sea Asia one of the premier maritime industry events in the Asia-Pacific… Leading mental health support provider MHSS is proud to confirm its commitment to diversity and inclusion with the appointment of two psychologists… Design & Development by P.KAN.DESIGNER Design & Development by P.KAN.DESIGNER Visitors to will be able to see for themselves how the flat-die pellet mill type 45–1000 works In addition to the production of substitute fuels and wood pellets these pellet mills also process large-volume plastic waste into compact which can then be fed into a chemical recycling process By recycling plastics in line with the circular economy companies not only conserve fossil resources but also reduce CO2 emissions Used textiles can also be prepared for recycling through pelletisation and used tyres through granulation The Amandus Kahl plant also meets the increasing demand for pelleted sewage sludge this organic waste product can be transported dust-free safely and cost-effectively to where it is needed Sewage sludge pellets are mainly used for thermal recovery the focus of interest is shifting to sewage sludge and sewage sludge ash particularly for the recovery of phosphorus for use in fertiliser production Sustainable feed processing is the central trade show topic at the 120m2 booth of the Reinbek-based company The reproduction of full articles - even if the source is mentioned - is only permitted with written consent from feedmagazine No responsibility or liability is assumed for the content of offers that can be accessed via links and do not originate from Deutschen Fachverlag From the production of species-appropriate animal feed to the processing of wheat or oats - AMANDUS KAHL has greatly expanded the field of application of the crushing roller mill Single drives open up new possibilities for animal feed producers Hauptnavigation: Nutzen Sie die Tabulatortaste Schließen Sie Untermenüs mit der Escape-Taste Das in Hongkong regristrierte Frachtschiff „Newnew Polar Bear“ Das Foto stammt vom finnischen GrenzschutzQuelle: picture alliance/dpa/Lehtikuva/Heikki Saukkomaa{"@context":"https://schema.org","@type":"ImageObject","contentUrl":"https://images.welt.de/67d9ae9e7de6aa7483842a49/ec4823adae2586749a5ddad637889051/ci23x11-w2000","caption":"Das in Hongkong regristrierte Frachtschiff „Newnew Polar Bear“ Das Foto stammt vom finnischen Grenzschutz","copyrightNotice":"picture alliance/dpa/Lehtikuva/Heikki Saukkomaa","creditText":"picture alliance/dpa/Lehtikuva/Heikki Saukkomaa","width":"2000"}Ein chinesischer Frachter soll womöglich mit Absicht eine Gaspipeline in der Ostsee zerstört haben Auf dem Meeresgrund stießen Taucher auf eine meilenlange Furche die vom nun geborgenen Anker des Schiffs stammen könnte Bewegungsdaten und weitere Indizien erhärten den Verdacht Die WELT als ePaper: Die vollständige Ausgabe steht Ihnen bereits am Vorabend zur Verfügung – so sind Sie immer hochaktuell informiert Weitere Informationen https://epaper.welt.de